Can Plant-Based supplements ease perimenopause? new trial seeks answers
NCT ID NCT07148011
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested plant-based health products in 900 perimenopausal women aged 37-55. Participants took either the active supplement or a placebo for 12 weeks. The goal was to see if the supplements improve common perimenopause issues like hot flashes, mood swings, and sleep problems.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- plant-based dietary supplement
- What this could lead to
- If it works, this could offer a natural option for managing perimenopause symptoms like hot flashes and mood changes.
- What could go wrong
- This is a completed trial, but results are not yet published. The supplement may work no better than placebo, and individual results can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
900 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
37 to 55 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults, aged 37 - 55 years at the time of electronic consent, inclusive of all ethnicities, races, and gender identities * Assigned sex at birth is female * Resides in the United States * Identifies menstrual status as perimenopausal * Has the opportunity for at least 30% improvement in their primary health outcome * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study Exclusion Criteria: * Reports being pregnant, trying to become pregnant, or breastfeeding * Unable to provide a valid US shipping address and mobile phone number * Reports current enrollment in another clinical trial * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * Unable to read and understand English * Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk. * Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure * Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products * Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk to participants * Reports an allergy to and/or disinterest in any of the possible study product ingredients * Lack of reliable daily access to the internet
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Perimenopause are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Radicle Science, Inc
Del Mar, California, 92014, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may soothe menopause symptoms — a trial puts it to the test
- Hormone therapy may shield menopausal hearts and brains — a trial puts it to the test
- AI could spot hidden heart risks in menopausal women
- Could a tiny ear device ease severe PMS and menopause symptoms?
- Wearable Brain-Zapping device aims to ease Period-Related mood and brain fog
- Can an online program ease menopause mood swings?